Skip to content

Botulinum Toxin Type A Combining Triamcinolone and 5-Fluorouracil in the Treatment of Scars: A Prospective, Open Clinical, Randomized Controlled Trial

Botulinum Toxin Type A Combining Triamcinolone and 5-Fluorouracil in the Treatment of Scars: A Prospective, Open Clinical, Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100049402
Enrollment
Unknown
Registered
2021-08-02
Start date
2021-08-05
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

scar

Interventions

Sponsors

Shanghai 9th Peoples Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Patients with age more than 18 years; 2.Length of scar is no less than 10 mm; 3.Initial Vancouver Scar Scale score is no less than 6; 4.Patients with good compliance.

Exclusion criteria

Exclusion criteria: 1. Women who are pregnant or planning to be pregnant within six months or who are breast-feeding; 2. Abnormal complete blood count or abnormal renal and liver function; 3. Patients had either Botulinum toxin type Atriamcinolone or 5- fluorouracil intralesional before in the same scar within 6 months; 4. Allergic to botulinum toxin type A, triamcinolone, 5-fluorouracil or lidocaine; 5. Diabetes or other basic diseases; 6. Immunosuppression or other status not suitable for treatment.

Design outcomes

Primary

MeasureTime frame
Vancouver Scar Scale;

Secondary

MeasureTime frame
Patient Scar Assessment Scale;length of scar;width of scar;

Countries

China

Contacts

Public ContactLiu Fei

Shanghai 9th Peoples Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Plasticliu@hotmail.com+86 13817377740

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026